• multiple myeloma - 2nd line (L2) 1
• myofibroblastic tumors
• neurofibroma
• neutropenia
• new pathology
• osteosarcoma
• ovarian cancer (OC) 9

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
• atezolizumab plus SoC
• avelumab based treatment
• avelumab alone
• avelumab plus pegylated liposomal doxorubicin
• avelumab plus SoC
• nivolumab based treatment
• Immune checkpoint association
• nivolumab plus ipilimumab
• poly ADP-ribose polymerase (PARP) inhibitor
• niraparib
• olaparib
• rucaparib
• target therapy
• multikinase inhibitor
• nintedanib

• versus all
• vs chemotherapy
• vs non platinum-based chemotherapy
• vs anthracyclines
• vs doxorubicin
• vs pegylated liposomal doxorubicin
• vs Standard of Care (SoC)
• vs placebo plus SoC
• vs immune chekpoint inhibitors
• vs anti-PD-(L)1
• vs nivolumab based treatment
• vs nivolumab alone
• vs poly ADP-ribose polymerase (PARP) inhibitor
• vs rucaparib
• vs VEGF(R) inhibitor
• vs bevacizumab based treatment
• vs bevacizumab plus carboplatin and paclitaxel

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Pathology:  metastatic/advanced OC (mOC) - 1st line (L1);   mOC - L1 - all population;   mOC - L1 - PDL1 positive;